Additionally, the 36-month beta value for LXEO is 3.04. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LXEO is 24.69M and currently, short sellers hold a 7.61% ratio of that float. The average trading volume of LXEO on February 21, 2025 was 249.24K shares.
LXEO) stock’s latest price update
The stock price of Lexeo Therapeutics Inc (NASDAQ: LXEO) has dropped by -9.64 compared to previous close of 4.46. Despite this, the company has seen a gain of 2.03% in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P.
LXEO’s Market Performance
LXEO’s stock has risen by 2.03% in the past week, with a monthly drop of -17.42% and a quarterly drop of -39.40%. The volatility ratio for the week is 10.19% while the volatility levels for the last 30 days are 11.38% for Lexeo Therapeutics Inc The simple moving average for the past 20 days is -19.79% for LXEO’s stock, with a -60.77% simple moving average for the past 200 days.
Analysts’ Opinion of LXEO
Many brokerage firms have already submitted their reports for LXEO stocks, with Robert W. Baird repeating the rating for LXEO by listing it as a “Outperform.” The predicted price for LXEO in the upcoming period, according to Robert W. Baird is $28 based on the research report published on June 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXEO reach a price target of $22. The rating they have provided for LXEO stocks is “Buy” according to the report published on June 06th, 2024.
Stifel gave a rating of “Buy” to LXEO, setting the target price at $20 in the report published on November 28th of the previous year.
LXEO Trading at -32.31% from the 50-Day Moving Average
After a stumble in the market that brought LXEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.33% of loss for the given period.
Volatility was left at 11.38%, however, over the last 30 days, the volatility rate increased by 10.19%, as shares sank -17.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.08% lower at present.
During the last 5 trading sessions, LXEO rose by +2.03%, which changed the moving average for the period of 200-days by -67.66% in comparison to the 20-day moving average, which settled at $5.02. In addition, Lexeo Therapeutics Inc saw -38.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXEO starting from Townsend Richard Nolan, who proposed sale 4,326 shares at the price of $4.41 back on Feb 19 ’25. After this action, Townsend Richard Nolan now owns shares of Lexeo Therapeutics Inc, valued at $19,091 using the latest closing price.
Robertson Jenny, the Officer of Lexeo Therapeutics Inc, proposed sale 2,101 shares at $4.41 during a trade that took place back on Feb 19 ’25, which means that Robertson Jenny is holding shares at $9,272 based on the most recent closing price.
Stock Fundamentals for LXEO
The total capital return value is set at -0.63. Equity return is now at value -107.21, with -75.77 for asset returns.
Based on Lexeo Therapeutics Inc (LXEO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.42. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -594.64.
Currently, EBITDA for the company is -66.67 million with net debt to EBITDA at 1.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.95.
Conclusion
In conclusion, Lexeo Therapeutics Inc (LXEO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
